PHAR
Pharming Group·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
PHAR fundamentals
Pharming Group (PHAR) released its earnings on Nov 6, 2025: revenue was 97.30M (YoY +29.99%), beat estimates; EPS was 0.1 (YoY +600.00%), beat estimates.
Revenue / YoY
97.30M
+29.99%
EPS / YoY
0.1
+600.00%
Report date
Nov 6, 2025
PHAR Earnings Call Summary for Q3,2025
- Revenue Surge: 30% YoY growth to $97.3M, driven by RUCONEST (+29%) and Joenja (+35%).
- Pediatric Growth: 54 U.S. pediatric Joenja patients identified, 1/3 on early access ahead of Jan 2026 launch.
- Pipeline Momentum: Upgraded 2025 guidance to $365-$375M, with KL1333 on track for 2027 readout.
- Financial Discipline: 4x operating profit growth to $16M, cash flow $32M, and G&A reduction to optimize capital allocation.
EPS
Revenue
Revenue & Expenses
PHAR has released its 2025 Q3 earnings report, with revenue of 97.29M, reflecting a YoY change of 29.98%, and net profit of 7.55M, showing a YoY change of 829.98%. The Sankey diagram below clearly presents PHAR's revenue sources and cost distribution.
Key Indicators
Pharming Group (PHAR) key financial stats and ratios, covering profitability, financial health, and leverage.
Pharming Group (PHAR)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Pharming Group (PHAR)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Pharming Group (PHAR)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Pharming Group (PHAR) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Pharming Group (PHAR) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
What is the revenue and EPS growth rate for Pharming Group year over year?What does Pharming Group do and what are its main business segments?What factors drove the changes in Pharming Group's revenue and profit?What is the market's earnings forecast for Pharming Group next quarter?What were the key takeaways from Pharming Group's earnings call?What guidance did Pharming Group's management provide for the next earnings period?What is Pharming Group's latest dividend and current dividend yield?Did Pharming Group beat or miss consensus estimates last quarter?
